Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label randomized phase 4 study of erenumab versus oral preventive therapy in adults with episodic migraine
MOH_2019-04-03_006066Phase 4Completed
- Sponsor
- Novartis
- Start
- Mar 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of erenumab in migraine (3 arms), sponsored by Novartis. Started Mar 2019; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on MOH_2019-04-03_006066.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-04-03_006066.